CA2728547A1 - Solid dosage formulations of telcagepant potassium - Google Patents

Solid dosage formulations of telcagepant potassium Download PDF

Info

Publication number
CA2728547A1
CA2728547A1 CA2728547A CA2728547A CA2728547A1 CA 2728547 A1 CA2728547 A1 CA 2728547A1 CA 2728547 A CA2728547 A CA 2728547A CA 2728547 A CA2728547 A CA 2728547A CA 2728547 A1 CA2728547 A1 CA 2728547A1
Authority
CA
Canada
Prior art keywords
oxo
solid dosage
pharmaceutical formulation
dihydro
azepan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2728547A
Other languages
English (en)
French (fr)
Inventor
Majid Mahjour
Dan Zhang
Aaron J. Moment
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2728547A1 publication Critical patent/CA2728547A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2728547A 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium Abandoned CA2728547A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13354208P 2008-06-30 2008-06-30
US61/133,542 2008-06-30
PCT/US2009/049009 WO2010002763A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Publications (1)

Publication Number Publication Date
CA2728547A1 true CA2728547A1 (en) 2010-01-07

Family

ID=41057505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728547A Abandoned CA2728547A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Country Status (16)

Country Link
US (1) US20100009967A1 (enExample)
EP (1) EP2303238A1 (enExample)
JP (2) JP2011526909A (enExample)
KR (1) KR20110025926A (enExample)
CN (1) CN102076330A (enExample)
AR (1) AR072395A1 (enExample)
AU (1) AU2009267145A1 (enExample)
CA (1) CA2728547A1 (enExample)
CR (1) CR20110038A (enExample)
DO (1) DOP2010000409A (enExample)
IL (1) IL209833A0 (enExample)
MX (1) MX2010014524A (enExample)
RU (1) RU2011103170A (enExample)
SV (1) SV2010003774A (enExample)
TW (1) TW201004954A (enExample)
WO (1) WO2010002763A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5243548B2 (ja) * 2007-10-25 2013-07-24 プロテウス デジタル ヘルス， インコーポレイテッド 情報システムのための流体伝達ポート
CA2722536A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
BR9808581A (pt) * 1997-03-13 2000-05-30 Hexal Ag Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Also Published As

Publication number Publication date
SV2010003774A (es) 2011-03-23
JP2011246478A (ja) 2011-12-08
US20100009967A1 (en) 2010-01-14
CR20110038A (es) 2011-03-16
WO2010002763A1 (en) 2010-01-07
KR20110025926A (ko) 2011-03-14
JP2011526909A (ja) 2011-10-20
MX2010014524A (es) 2011-02-24
DOP2010000409A (es) 2011-02-15
TW201004954A (en) 2010-02-01
RU2011103170A (ru) 2012-08-10
IL209833A0 (en) 2011-02-28
AR072395A1 (es) 2010-08-25
AU2009267145A1 (en) 2010-01-07
CN102076330A (zh) 2011-05-25
EP2303238A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
KR100738861B1 (ko) 베타-카르볼린 약학 조성물
KR101595169B1 (ko) 메트포민과 빌다글립틴을 포함하는 제제
EP2364142B1 (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
RU2716595C2 (ru) Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения
MX2008003882A (es) Formulacion de capsula de pirfenidona y excipientes farmaceuticamente aceptables.
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
RS56408B1 (sr) Čvrsti oblici doziranja bendamustina
TW201208667A (en) Pharmaceutical combinations
KR20250002778A (ko) Glp1 제약 조성물
TWI889851B (zh) 阿卡拉布替尼馬來酸鹽劑型
RS58214B1 (sr) Farmaceutski sastav koji sadrži kandesartan cileksetil i amlodipin
CA2728547A1 (en) Solid dosage formulations of telcagepant potassium
US10085991B2 (en) Formulation inhibiting effects of low acid environment
CA2432543A1 (en) Combination drugs
WO2009146608A1 (zh) 含有咪唑5-羧酸类衍生物的药用组合物，其制备方法及用途
JP2018168153A (ja) ６−｛２−［１−（６−メチル−３−ピリダジニル）−４−ピペリジニル］エトキシ｝−３−エトキシ−１，２−ベンゾイソオキサゾールの無水結晶性遊離塩基形態
CN110582278A (zh) 药物组合物及其用途
JP5824222B2 (ja) 固形製剤の製造方法
JP2025525407A (ja) エルラグルシブの経口剤形
TWI484955B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
CA2541045A1 (en) A descarbonylethoxyloratadine containing pharmaceutical composition
HK40083774A (en) Acalabrutinib maleate dosage forms
WO2022076709A1 (en) Formulation of a pan-jak inhibitor
WO2011009360A1 (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
KR20220129538A (ko) 렘보렉산트의 약물 물질 및 이를 포함하는 의약 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130702